Resumo el articulo de hoy de SNTA en SA con sus ultimos parrafos:
Insiders Are Buying And Buying at a Massive Rate
Insiders have been actively buying up shares of this cancer-focused biotech drug developer. The bulk of the purchases, representing seven different insiders and more than 2 million shares, have come in the $4.50 to $5 range. A SNTA director, Bruce Kovner, bought 200,000 shares for a $799,160 stake in the company recently, but was small in comparison to his purchase of 2 million shares for $4.65 last month. Simply visiting a page dedicated to SEC filings for the company reveals that persons inside the company are buying shares on a weekly basis. Substantial purchases have been made by Bruce Kovner, Bill Reardon, Safi Bachall and Vojo Vukovic. Note these are direct purchases, not simply exercising of warrants/options. This is extremely bullish activity, as insiders recognize the activity of ganetespib and the potential the drug has. Further, the stock is still oversold, considering it was recently above $10.00.
Analysts Are Very Bullish
Recent analyst comments suggest there is massive upside from the current price of $5.20. JMP's Mike King upgraded the shares to Outperform and set an $11 price target. In a recent market current on Seeking Alpha, it was noted Adam Feurstein does not agree with the potential of the data, although he is not a specialist in biostatistics, medicine or epidemiology. His comments should be considered, yet the data speaks for itself. Jefferies' Thomas Wei says "incremental geographic data from [a] recent analysis the GALAXY-1 trial [will] support the efficacy profile" of the drug. The analyst has a solid buy rating and a $22 price target on the stock, a premium of nearly 400% from the current $5.20 price. Of the 7 buy ratings and two hold ratings, the lowest price target is $6.00, a premium of 15% higher than the current $5.20 price, while the average price target is $11.75, or a premium of 125%.
Takeaway: There is a Ton of Upside Left
The stock has bounced off the 52-week low of $3.76, but still far below the pre GALAXY-1 data release price of $10.00 in early May. In the near term, I see the stock approaching $8.50 as we get closer to the release of the GALAXY-2 data, and if the data is inline or superior to expectations, the stock could easily hit $11.00, with an excellent chance of being considered for a larger trial and/or ultimate FDA approval down the road.
